Early cART with or without CTL Infusion in Acute HIV

Phase 3, randomised, open-label trial of autologous HIV-specific CD8+ cytotoxic T cells in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoints: Change from baseline in HIV DNA quantification at the interruption of cART at 96 weeks and Number of patients who achieve virological remission at 120 weeks. Status: unknown.